Results 181 to 190 of about 21,646 (232)

Prescribing patterns and clinician preferences for direct oral anticoagulant use in unusual site venous thromboembolism: a cross-sectional analysis from the Direct oral anticoagulants in Unusual Site venous Thromboembolism (DUST) study. [PDF]

Res Pract Thromb Haemost
Riva N, Bertoletti L, Chistolini A, De Stefano V, Barbar S, Donadini MP, Sartori MT, Couturaud F, Sartori M, Gatt A, Cohen O, Fantoni C, Kaatz S, Mavri A, Mahé I, Catella J, Ruiz-Artacho P, Ghigliotti G, Jara-Palomares L, Podda GM, Squizzato A, Rojnuckarin P, Leentjens J, Sevestre MA, Ageno W.   +24 more
europepmc   +1 more source

Idarucizumab for dabigatran overdose

Clinical Toxicology, 2016
An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Marijke, Peetermans, Charles, Pollack, Paul, Reilly, Laurens, Liesenborghs, Marc, Jacquemin, Jerrold H, Levy, Jeffrey I, Weitz, Peter, Verhamme   +7 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Removal of Dabigatran by Hemodialysis

American Journal of Kidney Diseases, 2013
Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that invasive laboratory testing and dose adjustment is not necessary.
William E Dager
exaly   +3 more sources

The trouble with dabigatran

BMJ, 2014
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake, Charlton, Rita, Redberg
openaire   +2 more sources

Dabigatran Etexilate

Drugs, 2008
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire   +2 more sources

Dabigatran

2023
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire   +1 more source

Use of dabigatran with antiretrovirals

HIV Medicine, 2019
ObjectivesTheoretical and untested interactions between antiretrovirals and direct‐acting oral anticoagulants have limited the use of this new class of anticoagulant in people with HIV infection. This case series, the first of its kind, reports on the successful concurrent use of the direct‐acting oral anticoagulant dabigatran and antiretroviral ...
J Perram, E O'Dwyer, C Holloway
openaire   +2 more sources

Gastrointestinal disorders and dabigatran

Scandinavian Journal of Gastroenterology, 2012
Anticoagulants play an important role in the prevention and treatment of a variety of acute and chronic thromboembolic disorders such as primary prevention and treatment of venous thromboembolism or prevention of stroke and systemic embolism in atrial fibrillation just to name of few.
Arthur, Hoffman, P R, Galle
openaire   +2 more sources